<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246632</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-CVI-5248</org_study_id>
    <nct_id>NCT04246632</nct_id>
  </id_info>
  <brief_title>CapsoCam® Colon Capsule Endoscope (CCE) Compared to Colonoscopy (OC)</brief_title>
  <official_title>Prospective, Open Label, Pilot Study of the CapsoCam® Colon Capsule Endoscope (CCE) Compared to Colonoscopy (OC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capso Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capso Vision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-significant risk pilot study is designed to evaluate safety and performance of the
      CapsoCam® Colon capsule endoscope in patients who meet the eligibility criteria and are
      scheduled for colonoscopy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2020</start_date>
  <completion_date type="Anticipated">August 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multi-Center; Prospective, Open Label, Non-Significant Risk, Pilot Study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>PI is masked to Capsule results and capsule reader is masked to colonoscopy results.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Assessments</measure>
    <time_frame>Day 1</time_frame>
    <description>Determine the Accuracy of CapsoCam® to detect and measure size of colon polyps relative to the colonoscopy procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessments: Incidence of device related serious adverse events (SAEs) and unanticipated adverse device effects (UADEs)</measure>
    <time_frame>Day 1-3</time_frame>
    <description>All adverse events including SAEs/UADEs will be assessed at all visits. Incidence of serious adverse events (SAEs) and unanticipated adverse device effects (UADEs) will be reported. A serious adverse event is one that meets the definition outlined in Section 8 of this protocol.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colonoscopy</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CapsoCam Colon Capsule Endoscopy</intervention_name>
    <description>CapsoCam® Colon is intended to provide visualization of the colon and the detection of colon polyps in adults.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between the ages of 50 and 75 years old

          2. Subject meets at least one of the following criteria for increased risk for polyps:

               1. Recent history (within 6 months) of positive FIT/iFOBT or Cologuard test

               2. Older than 55 years of age, without prior history of colonoscopy

               3. Has had a positive colonoscopy ≥ 5 years prior to screening visit

               4. And/or having at least two of the following risk factors:

                    -  Current smoker

                    -  BMI of ≥30

                    -  Family history (blood relative) of colorectal cancer

                    -  Sedentary lifestyle

                    -  Low fiber/ high fat diet

          3. No contraindication for capsule endoscopy or colonoscopy

          4. Committed to undergo a colonoscopy, independent of this study within 8 weeks of
             Capsule ingestion

          5. Choose to participate and must have signed the IRB-approved informed-consent document
             and agreed to release colonoscopy images and results report to Sponsor

        Exclusion Criteria:

          1. History of negative colonoscopy within the last 10 years

          2. History of incomplete colonoscopy

          3. Impaired cardiac function assessed as greater than NYHA Class II

          4. History of small- or large-bowel obstructive condition

          5. Known history of Crohn's disease, swallowing disorder, ulcerative colitis, ischemic
             bowel disease and/or radiation enteritis

          6. Known history of NSAID enteropathy and stricture resulting from taking NSAIDs on a
             regular basis that, in the opinion of the Investigator, would put the patient at
             greater risk for capsule endoscope retention

          7. Unable to follow or tolerate fasting, bowel preparation, and other study procedures

          8. Known allergy to ingredients used in bowel preparation and boosters

          9. Daily and/or regular use of narcotics

         10. Known or suspected AIDS

         11. Uncompensated cirrhosis

         12. Prior abdominal radiation therapy

         13. Diagnosis of anorexia or bulimia

         14. History of or suspicion for: strictures, volvulus or intestinal obstruction; internal
             hernias or abdominal surgeries that the Investigator considers as an exclusion

         15. Known or suspected megacolon

         16. Scheduled to undergo MRI examination within 7 days after ingestion of the capsule

         17. Has known slow gastric-emptying time or confirmed diagnosis of gastroparesis

         18. Pregnant or nursing or is of child-bearing potential and does not practice medically
             acceptable methods of contraception. Women of childbearing potential (WOCBP) must have
             a negative urine pregnancy test at screening.

         19. Any documented medical or psychological condition or significant concurrent illness
             which, in the Investigator's opinion, would make it unsafe for the subject to
             participate in this research study

         20. Are currently enrolled in, or participated in within the last 30 days, another
             clinical study

         21. Chronic constipation as defined by &lt;3 bowel movements per week for at least 3 months
             prior to Screening, or the use of routine laxatives (other than fiber) to attain r
             regular bowel movements for at least 3 months prior to Screening

         22. History of diabetes in which the prolonged fasting schedule could impose additional
             safety risks, as determined by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maggie LeDang</last_name>
    <phone>4089818754</phone>
    <email>maggie.ledang@capsovision.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Silicon Valley Research Institute, Inc.</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mai I Nguyen</last_name>
      <phone>408-515-2428</phone>
      <email>mai.nguyen@admin-sjgi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CapsoVision Research Clinic</name>
      <address>
        <city>Saratoga</city>
        <state>California</state>
        <zip>95070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David S. Shields, MD</last_name>
      <phone>408-508-5641</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Michigan Clinical Research Center</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rochelle Copeland</last_name>
      <email>rcopeland@gastro-assoc-wm.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All IPD will be kept confidential. Safety events/concerns will be shared will all sites without exposing PHI.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

